DTech Liquidating

DTech Liquidating EBIT CAGR 5Y

Delisted

The EBIT CAGR (5 Year) of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 120.73 %. In the previous year, EBIT CAGR (5 Year) was 120.73 % — a change of 0.00% (lower).

EBIT CAGR 5Y

120.73 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of DTech Liquidating is 2023 120.73 % . EBIT CAGR (5 Year) of DTech Liquidating was 2022 120.73 % . It decreases by 0.00% lower compared to the previous year.

The DTech Liquidating EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2016
120.73 USD
Jan 1, 2017
120.73 USD
Jan 1, 2018
120.73 USD
Jan 1, 2019
120.73 USD
Jan 1, 2020
120.73 USD
Jan 1, 2021
120.73 USD
Jan 1, 2022
120.73 USD
Jan 1, 2023
120.73 USD
The DTech Liquidating EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %0.00%
120.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

EBIT CAGR (5 Year) of DTech Liquidating is 120.73 % in 2023.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — DTech Liquidating

All Key Metrics — DTech Liquidating